Analysis of the Association between CIMP and BRAF V600E in Colorectal Cancer by DNA Methylation Profiling
Toshinori Hinoue, Daniel J. Weisenberger, Fei Pan et al. · 2009
Read Analysis of the Association between CIMP and BRAF V600E in Colorectal Cancer by DNA Methylation Profiling by Toshinori Hinoue, Daniel J. Weisenberger, Fei Pan et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0008357.txt.
Introduction
Toshinori Hinoue and his team wrote in PLOS ONE in 2009 about a mark found in some bowel cancers. A set of bowel tumors shows a trait in which many gene sites gain a small chem tag, known as methylation. The set of sites hit is more or less the same in each such tumor. A changed gene named BRAF, in a form called V600E, shows up most times in the same tumors. The tie between the trait and that gene form called for a close look.
They mapped the tags at a large set of gene sites in the tumors. Wide maps show how firm and how tight the tie is. Tag forms may help sort bowel cancers for the right care. The work adds fine points to the chart of this cancer's types.
Catalog record
| CREATOR | Toshinori Hinoue, Daniel J. Weisenberger, Fei Pan et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008357
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Analysis of the Association between CIMP and BRAF V600E in Colorectal Cancer by DNA Methylation Profiling Authors: Toshinori Hinoue, Daniel J. Weisenberger, Fei Pan, Mihaela Campan, Myungjin Kim, Joanne Young, Vicki L. Whitehall, Barbara A. Leggett, Peter W. Laird Published: 2009, PLOS ONE DOI: 10.1371/journal.pone.0008357 ABSTRACT A CpG island methylator phenotype (CIMP) is displayed by a distinct subset of colorectal cancers with a high frequency of DNA hypermethylation in a specific group of CpG islands. Recent studies have shown that an activating mutation of BRAF (BRAF V600E ) is tightly associated with CIMP, raising the question of whether BRAF V600E plays a causal role in the development of CIMP or whether CIMP provides a favorable environment for the acquisition of BRAF V600E . We employed Illumina GoldenGate DNA methylation technology, which interrogates 1,505 CpG sites in 807 different genes, to further study this association. We first examined whether expression of BRAF V600E causes DNA hypermethylation by stably expressing BRAF V600E in the CIMP-negative, BRAF wild-type COLO 320DM colorectal cancer cell line. We determined 100 CIMP-associated CpG sites and examined changes in DNA methylation in eight stably transfected clones over multiple passages. We found that BRAF V600E is not sufficient to induce CIMP in our system. Secondly, considering the alternative possibility, we identified genes whose DNA hypermethylation was closely linked to BRAF V600E and CIMP in 235 primary colorectal tumors. Interestingly, genes that showed the most significant link include those that mediate various signaling pathways implicated in colorectal tumorigenesis, such as BMP3 and BMP6 (BMP signaling), EPHA3 , KIT , and FLT1 (receptor tyrosine kinases) and SMO (Hedgehog signaling). Furthermore, we identified CIMP-dependent DNA hypermethylation of IGFBP7 , which has been shown to mediate BRAF V600E -induced cellular senescence and apoptosis. Promoter DNA hypermethylation of IGFBP7 was associated with silencing of the gene. CIMP-specific inactivation of BRAF V600E -induced senescence and apoptosis pathways by IGFBP7 DNA hypermethylation might create a favorable context for the acquisition of BRAF V600E in CIMP+ colorectal cancer. Our data will be useful for future investigations toward understanding CIMP in colorectal cancer and gaining insights into the role of aberrant DNA hypermethylation in colorectal tumorigenesis. INTRODUCTION Aberrant DNA methylation at CpG islands has been widely observed in cancer. Promoter CpG island hypermethylation associated with inactivation of selected tumor suppressor genes appears to be critical in tumors from inception through to maintenance of the tumor phenotype [1] . Distinct subgroups of several types of human cancers have been proposed to have a CpG island methylator phenotype (CIMP) in which an exceptionally high frequency of cancer-specific DNA hypermethylation is found [2] , [3] . Although this concept has been controversial [4] , we have confirmed the existence of CIMP in colorectal cancer in a large-scale comprehensive study [5] . CIMP in colorectal cancer may arise through a distinct pathway originating in certain subtypes of serrated polyps [6] and is observed in approximately 15% of all colorectal cancer cases [5] , [7] . Features associated with CIMP in colorectal cancer include gender (female), proximal location, and poorly differentiated or mucinous histology [3] , [5] , [7] , [8] . Our study using a newly developed CIMP marker panel in colorectal cancers demonstrated that sporadic microsatellite instability (MSI+) occurs as a consequence of CIMP-associated MLH1 DNA hypermethylation [5] . Furthermore, we found a strong association of CIMP with the presence of an activated mutant form of BRAF (BRAF V600E ) [5] . Both CIMP and BRAF mutations have been reported in the earliest stages of colorectal neoplasia: CIMP in apparently normal mucosa of patients predisposed to multiple serrated polyps [9] and BRAF mutations in aberrant crypt foci [10] . The RAS-RAF-MEK-ERK signaling pathway is frequently hyperactivated in colorectal cancer. KRAS mutations occur most frequently in 30–40% of all colorectal cancers [11] and BRAF mutations are present at a frequency of 5–22%, in which the constitutively activated BRAF V600E variant accounts for ∼90% of all the BRAF mutations [12] . Mutations in KRAS and BRAF are generally mutually exclusive, implying equivalent downstream effects in tumorigenesis [13] . However, recent studies have indicated that mutations of these genes might play distinct roles in tumor initiation and/or maintenance [10] , [14] . The extremely tight association between BRAF V600E and CIMP raises the question of whether BRAF V600E plays a causal role in the development of CIMP or whether CIMP-associated promoter hypermethylation provides a favorable setting for the acquisition of BRAF V600E . In this study, we searched for possible molecular explanations for the association between BRAF V600E and CIMP using the Illumina GoldenGate DNA methylation platform, which examines the DNA methylation status of 1,505 CpG sites located at 807 genes. The GoldenGate DNA methylation assay has been widely used in various studies and is now a standard method for DNA methylation analysis [15] – [24] . Findings obtained from the commercially available “GoldenGate Methylation Cancer Panel I”, in particular, have been validated using various other techniques [15] – [17] , [22] , [23] , making it a reliable source for DNA methylation measurements across 1,505 loci. We were not able to demonstrate a causal contribution of BRAF V600E to CIMP in our cell culture system. However, we identified genes whose DNA hypermethylation was significantly linked with BRAF V600E in primary colorectal tumors. Inactivation of these specific genes in the context of CIMP might drive the acquisition of BRAF V600E in CIMP+ colorectal tumors. RESULTS We first sought to determine whether expression of BRAF V600E would induce DNA hypermethylation at CpG sites associated with CIMP in an in vitro cell culture system. Since primary colonic epithelial cells were not readily available, we screened for colorectal cancer cell lines that do not have substantial DNA methylation at CIMP-defining loci and carry wild-type forms of both BRAF and KRAS . Such cell lines would serve as suitable systems for the introduction of BRAF V600E . We selected 21 colorectal cancer cell lines, characterized their DNA methylation profiles, and determined their BRAF and KRAS mutation status ( Figure 1 ). We used MethyLight to assess the DNA methylation status of five CIMP-defining markers previously identified in our laboratory [5] . Using a PMR (percent of methylated reference) of ≥10 as a threshold for positive methylation, we identified six cell lines that lacked DNA methylation for all five CIMP-specific markers ( Figure 1 ). To test our hypothesis, we initially chose the BRAF and KRAS wild-type Caco-2 and COLO 320DM cell lines for their ease in culturing and transfection. However, the study described below is limited to COLO 320DM cells, since we were not able to isolate any stably transfected Caco-2 clones that showed detectable level of BRAF V600E expression (data not shown). MethyLight was used to assess the DNA methylation status of five CIMP-defining markers. A PMR of ≥10 was used as a threshold for positive methylation. Black boxes indicate PMR ≥10, and white boxes indicate PMR <10. The DNA methylation frequencies of the five CIMP markers increase from top to bottom. Microsatellite instability status for each cell line is listed as microsatellite stable (MSS) or harboring instability (MSI). The mutation status of BRAF exon 15 and KRAS exon 2 are listed. STABLE TRANSFECTION OF BRAF V600E